Neuropeptide Y mediates cardiac hypertrophy through microRNA-216b/FoxO4 signaling pathway.


Journal

International journal of medical sciences
ISSN: 1449-1907
Titre abrégé: Int J Med Sci
Pays: Australia
ID NLM: 101213954

Informations de publication

Date de publication:
2021
Historique:
received: 26 07 2020
accepted: 13 10 2020
entrez: 4 1 2021
pubmed: 5 1 2021
medline: 7 9 2021
Statut: epublish

Résumé

Cardiac hypertrophy (CH) is a major risk factor for heart failure accompanied by maladaptive cardiac remodeling. The role and potential mechanism of neuropeptide Y (NPY) in CH are still unclear. We will explore the role and the mechanism of NPY inactivation (NPY-I) in CH caused by pressure overload. Abdominal aortic constriction (AAC) was used to induce CH model in rats. NPY or angiotensin II (Ang II) was used to trigger CH model

Identifiants

pubmed: 33390770
doi: 10.7150/ijms.51133
pii: ijmsv18p0018
pmc: PMC7738963
doi:

Substances chimiques

FOXO4 protein, rat 0
Forkhead Transcription Factors 0
MIRN216 microRNA, rat 0
MicroRNAs 0
Neuropeptide Y 0
Npy1r protein, rat 0
Receptors, G-Protein-Coupled 0
Receptors, Neuropeptide 0
Angiotensin II 11128-99-7
Arginine 94ZLA3W45F
BIBO 3304 O35HK034KO

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

18-28

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

Cardiovasc Diagn Ther. 2019 Dec;9(6):535-544
pubmed: 32038943
J Exp Med. 2005 Dec 5;202(11):1527-38
pubmed: 16330815
Peptides. 1997;18(3):445-57
pubmed: 9145434
J Am Heart Assoc. 2016 Feb 18;5(2):
pubmed: 26892527
EXS. 2006;(95):113-22
pubmed: 16383001
EXS. 2006;(95):89-103
pubmed: 16382999
Curr Opin Nephrol Hypertens. 2005 Jan;14(1):25-32
pubmed: 15586012
Cell Physiol Biochem. 2015;37(1):94-104
pubmed: 26303143
J Hypertens. 2010 Aug;28(8):1745-51
pubmed: 20543711
Circ Res. 2015 Nov 6;117(11):967-77
pubmed: 26438688
Am J Physiol Renal Physiol. 2007 Dec;293(6):F1811-7
pubmed: 17804485
Cell Physiol Biochem. 2015;35(3):899-912
pubmed: 25633415
Hypertension. 2016 Sep;68(3):654-66
pubmed: 27432858
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1595-600
pubmed: 10660688
Front Physiol. 2018 Sep 19;9:1281
pubmed: 30283345
Mol Cell Biochem. 2013 Jul;379(1-2):1-6
pubmed: 23660952
Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2188-97
pubmed: 18835922
Pharmacol Ther. 2011 Jul;131(1):91-113
pubmed: 21439311
Nat Rev Mol Cell Biol. 2013 Feb;14(2):83-97
pubmed: 23325358
PLoS One. 2011 May 09;6(5):e19481
pubmed: 21573063
Lancet. 1983 May 7;1(8332):1008-10
pubmed: 6133058
Mol Cell Biochem. 2013 Apr;376(1-2):189-95
pubmed: 23358924
Peptides. 2014 Nov;61:1-6
pubmed: 25149360
Int J Clin Pract. 2008 Sep;62(9):1432-40
pubmed: 18793378
Cell Death Dis. 2018 Jun 7;9(6):694
pubmed: 29880830
J Pharmacol Exp Ther. 2006 Dec;319(3):1286-96
pubmed: 16973886
Biomed Pharmacother. 2019 Aug;116:108977
pubmed: 31103821
Mol Ther Nucleic Acids. 2016 Mar 15;5:e296
pubmed: 26978580
Am J Physiol Regul Integr Comp Physiol. 2013 Dec 15;305(12):R1411-20
pubmed: 24005254
Mol Ther Nucleic Acids. 2018 Mar 2;10:387-397
pubmed: 29499950
Cardiovasc Res. 2015 Sep 1;107(4):522-33
pubmed: 25994172
Front Pharmacol. 2019 Oct 24;10:1268
pubmed: 31708788
Protein Pept Lett. 2020;27(9):878-887
pubmed: 32297569
Cardiovasc Res. 2018 Oct 1;114(12):1617-1628
pubmed: 29850786
Cardiovasc Res. 1990 Feb;24(2):102-8
pubmed: 2328516
Curr Top Med Chem. 2007;7(17):1692-703
pubmed: 17979778
Heart. 2013 Aug;99(16):1198-203
pubmed: 23403409
J Am Coll Cardiol. 2014 Jun 3;63(21):2177-87
pubmed: 24583309
Am J Transl Res. 2018 Sep 15;10(9):2890-2900
pubmed: 30323875
J Genet Genomics. 2016 Jul 20;43(7):421-30
pubmed: 27461754
Regul Pept. 2005 Feb 15;125(1-3):9-15
pubmed: 15582708
Int J Mol Sci. 2016 May 18;17(5):
pubmed: 27213331
Proc Natl Acad Sci U S A. 1982 Sep;79(18):5485-9
pubmed: 6957876

Auteurs

Jinghao Wang (J)

Department of Pharmacy, the First Affiliated Hospital, Jinan University, Guangzhou 510630, China.

Dan Hao (D)

Department of Cardiology, the First Hospital of Harbin, Harbin 150010, China.

Lingfeng Zeng (L)

Department of Pharmacy, the First Affiliated Hospital, Jinan University, Guangzhou 510630, China.

Qianhui Zhang (Q)

Department of Pharmacology, Harbin Medical University-Daqing, Daqing, Heilongjiang 163319, China.

Wei Huang (W)

Department of Pharmacology, Harbin Medical University-Daqing, Daqing, Heilongjiang 163319, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH